MDA 2025: DYNE-101 improves finger function in DM1 clinical trial
Treatment with DYNE-101 is leading to improvements in muscle function — with notable gains in finger function — among people with myotonic dystrophy type 1 (DM1) in a Phase 1/2 clinical trial, according to updated interim data. DM1 patients given the experimental therapy in the ongoing ACHIEVE study…